Join our daily newsletter At The Bell to receive exclusive market insights
- Houston We Have’s (HWH) wholly owned subsidiary, ECHOiQ, joins forces with Extential Solutions to provide cardiology software
- The strategic partnership was formed to integrate ECHOiQ’s artificial intelligence-based Enhanced Screening Program (ESP) technology with the current echocardiogram reporting and data analytics software provided by Extential
- HWH says this is a significant step towards deployment of the company’s ESP to benefit of reporting clinicians
- Houston We Have last traded at 17 cents at 2:30 pm AEST
Houston We Have’s (HWH) wholly owned subsidiary, ECHOiQ, has joined forces with Extential Solutions to provide cardiology software.
The strategic partnership was formed to integrate ECHOiQ’s artificial intelligence-based Enhanced Screening Program (ESP) technology with the current echocardiogram reporting and data analytics software provided by Extential.
“This partnership has the potential to achieve the kind of step-change in clinical risk identification capability that can reshape the power of diagnostic Cardiology,” said Extential Solutions CEO, Tom Mok.
Extential currently operates two platforms for echocardiographs, the Extential Solutions Clinical Reporting Platform and the Extential Solutions Data Analytics Platform.
The first allows sonographers and clinicians to efficiently create, edit and sign off on reports after the echocardiogram has been performed, while the second provides the ability for users to integrate, transform and analyse their retrospective clinical and administrative data.
ECHOiQ and Extential will set out the terms and operating conditions which the parties will collaborate under, with the aim of integrating ECHOiQ’s AI into Extential’s platforms.
This new collaboration will trial the integration of ECHOiQ’s Enhanced Screening Program for Aortic Stenosis into existing echocardiographic reporting workflows. This is hoped to improve the diagnostic identification of patients at risk of aortic stenosis, which is considered one of the most common, and highly treatable, forms of heart valve disease.
HWH says this is a significant step towards deployment of the company’s ESP to benefit of reporting clinicians.
“This should see fast, actionable deployment of our solution, creating impact in supporting earlier identification of patients displaying an “at-risk phenotype” for aortic stenosis – the first of a number of cardiac conditions being targeted by ECHOiQ,” said ECHOiQ Chairman, Andrew Grover.
Houston We Have last traded at 17 cents at 2:30 pm AEST.
